For the study, 18,201 patients with atrial fibrillation and at least 1 additional risk factor for stroke were randomized to apixaban (n = 9,120; 5 mg twice daily, or 2.5 mg twice daily in selected ...

ELIQUIS® (apixaban) was ... Among patients on warfarin, time in therapeutic INR (International Normalized Ratio) range of 2.0-3.0 was a median of 66.0 percent and mean of 62.2 percent, ...

The INR was elevated in only 21 percent of patients tested with rivaroxaban and in no patients with apixaban. In patients with bleeding, the INR was elevated in 5 of 8 with rivaroxaban but in none ...

AMSTERDAM, the Netherlands— The oral factor Xa inhibitor apixaban (Eliquis, Pfizer/Bristol-Myers Squibb) was as effective as standard enoxaparin plus warfarin in treating acute venous ...

The new analysis is the first to compare apixaban, a NOAC, to traditional warfarin in terms of the risk for intracranial hemorrhage. The trial enrolled more than 18,000 patients in North America ...

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients.

The INR was elevated in only 21 percent of patients tested with rivaroxaban and in no patients with apixaban. In patients with bleeding, the INR was elevated in 5 of 8 with rivaroxaban but in none ...

Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin ... 78.5% of patients had an INR <3.0 before the event.

Patients were randomized to treatment with Eliquis 5 mg orally twice daily (or 2.5 mg twice daily in selected patients, representing 4.7 percent of all patients) or warfarin (target INR range 2.0 ...

Rivaroxaban (Xarelto) was also associated with higher risk than apixaban (42.94 vs 20.05 per 1,000 person-years, HR 2.15, 95% CI 1.18-3.94), again with a stronger association in those using ART ...

Patients were randomized to receive either apixaban (n=9,120) 5 mg twice daily (2.5 mg twice daily in selected patients) or warfarin (n=9,081) dosed to achieve a target INR (International ...